Prelude (PRLD) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

$5.7M

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$13.9M

Net income growth (year over year)

+55.43%

Net margin

—

Return on equity

−57.73%

EPS (trailing twelve months)

−$0.73

Book value per share

$1.68

P/E (trailing twelve months)

—

Price to book

1.98

Debt to assets

29.38%

Payout ratio

—

Dividend yield

—

Company profile

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

• How do I buy stock in Prelude (PRLD)?

  PRLD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.